[Present and future of clinical application of myoblast].
OBJECTIVE
To introduce the current situation and future of myoblast transfer therapy (MTT) in clinical application.


METHODS
The latest fifteen-year literatures were extensively reviewed, concerning gene therapy for Duchenne's muscular dystrophy, Parkinson's disease, myelopathy, permanent facial paralysis, angiocardiopathy, injuries of bone, joint and muscle, hematopathy, and pituitary dwarf.


RESULTS
In medical field, MTT is an ideal method to treat some common diseases. The problems were immunologic rejection and better carriers for myoblasts implantation.


CONCLUSIONS
It is the focus on the use of myoblast as a vector to carry exogenous gene in some disease therapy. The major problems of MTT include transplantation immunity, cell fusion and target protein expression. It is easy to gain, culture and transfuse to the host for myoblasts, these merits are beneficial to clinical application.
Liu
Libin
L
Department of Neurology, West China Hospital, Sichuan University, Chengdu Sichuan, 610041, PR China. liulibin@sohu.com
Zhou
Hongyu
H
D000818:Animals; D009202:Cardiomyopathies / Q000628:therapy; D002318:Cardiovascular Diseases / Q000628:therapy*; D002454:Cell Differentiation; D017690:Cell Transplantation; D002478:Cells, Cultured; D015316:Genetic Therapy / Q000379:methods*; D006801:Humans; D051379:Mice; D020388:Muscular Dystrophy, Duchenne / Q000628:therapy; D032448:Myoblasts, Skeletal / Q000166:cytology / Q000637:transplantation*; D009422:Nervous System Diseases / Q000628:therapy*; D051381:Rats